4f4c837的个人主页 - 老虎社区

4f4c837

暂无个人介绍

IP属地：未知

18关注

0粉丝

0主题

0勋章

2021-12-22

Interesting

抱歉，原内容已删除

2021-12-22

Interesting

抱歉，原内容已删除

2021-12-22

Interesting

10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>

2021-12-22

Interesting

Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos股价暴跌87%，分析师因lirentelimab数据“令人失望”而下调评级</blockquote>

2021-12-22

Interesting

Stocks trade mixed after rally, with tech under pressure<blockquote>股市反弹后涨跌互现，科技股承压</blockquote>

2021-12-22

Interesting

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4089174425482880","uuid":"4089174425482880","gmtCreate":1626139762421,"gmtModify":1640189757944,"name":"4f4c837","pinyin":"meowier","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":18,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691625975,"gmtCreate":1640186032395,"gmtModify":1640186032395,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691625975","repostId":"2193192429","repostType":4,"isVote":1,"tweetType":1,"viewCount":2625,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691622121,"gmtCreate":1640185928643,"gmtModify":1640185971826,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691622121","repostId":"2193196162","repostType":4,"isVote":1,"tweetType":1,"viewCount":2364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691622066,"gmtCreate":1640185916183,"gmtModify":1640185916183,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691622066","repostId":"1188142807","repostType":4,"repost":{"id":"1188142807","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640181395,"share":"https://www.laohu8.com/m/news/1188142807?lang=zh_CN&edition=full","pubTime":"2021-12-22 21:56","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188142807","media":"Benzinga","summary":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Researc","content":"<p><ul>  <li>Barclays lifted the price target on&nbsp;<b>FactSet Research Systems Inc.</b>&nbsp;from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>  <li>HC Wainwright &amp; Co. raised the price target on&nbsp;<b>Chimerix, Inc.</b>&nbsp;from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>  <li>Bernstein raised&nbsp;<b>PACCAR Inc</b>&nbsp;price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>  <li>Jefferies cut&nbsp;<b>Adagio Therapeutics, Inc.</b>&nbsp;price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>  <li>Barclays boosted the price target for&nbsp;<b>NIKE, Inc.</b>&nbsp;from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>  <li>Needham lowered the price target on&nbsp;<b>Cognyte Software Ltd.</b>&nbsp;from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>  <li>Jefferies cut&nbsp;<b>ALX Oncology Holdings Inc.</b>&nbsp;price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>  <li>Bernstein reduced the price target for&nbsp;<b>AGCO Corporation</b>&nbsp;from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>  <li>RBC Capital raised&nbsp;<b>Consolidated Edison, Inc.</b>&nbsp;price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>  <li>Oppenheimer cut&nbsp;<b>Biogen Inc.</b>&nbsp;price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li> </ul></p><p><blockquote><ul><li>巴克莱上调目标价<b>FactSet研究系统公司。</b>从450美元到550美元。FactSet Research股价在盘前交易中上涨1.1%，至479.89美元。</li><li>HC Wainwright&amp;Co.上调目标价<b>奇梅里克斯公司。</b>从21美元到24美元。Chimerix股价在盘前交易中上涨4.4%至6.42美元。</li><li>伯恩斯坦提出<b>帕卡尔公司</b>目标价为94美元至98美元。PACCAR股价在盘前交易中上涨0.8%至84.04美元。</li><li>杰弗里斯削减<b>柔板治疗公司。</b>目标价为46美元至10美元。Adagio Therapeutics股价在盘前交易中下跌7.3%至9.54美元。</li><li>巴克莱提高了目标价<b>耐克公司。</b>从185美元到195美元。耐克股价在盘前交易中上涨0.2%，至166.98美元。</li><li>Needham将目标价下调至<b>科尼特软件有限公司。</b>从36美元到19美元。Cognyte Software股价在盘前交易中下跌1%，至15.54美元。</li><li>杰弗里斯削减<b>ALX肿瘤控股公司。</b>目标价为65美元至25美元。ALX Oncology Holdings股价在盘前交易中下跌1.5%至22.57美元。</li><li>伯恩斯坦降低了目标价<b>AGCO公司</b>从177美元到127美元。爱科股价在盘前交易中下跌1%，至112.95美元。</li><li>加拿大皇家银行筹集的资金<b>联合爱迪生公司。</b>目标价为78美元至85美元。联合爱迪生公司股价周二下跌0.8%，收于83.37美元。</li><li>奥本海默切<b>百健公司。</b>目标价从390美元到350美元。Biogen股价在盘前交易中下跌0.1%，至234.50美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 21:56</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><ul>  <li>Barclays lifted the price target on&nbsp;<b>FactSet Research Systems Inc.</b>&nbsp;from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>  <li>HC Wainwright &amp; Co. raised the price target on&nbsp;<b>Chimerix, Inc.</b>&nbsp;from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>  <li>Bernstein raised&nbsp;<b>PACCAR Inc</b>&nbsp;price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>  <li>Jefferies cut&nbsp;<b>Adagio Therapeutics, Inc.</b>&nbsp;price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>  <li>Barclays boosted the price target for&nbsp;<b>NIKE, Inc.</b>&nbsp;from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>  <li>Needham lowered the price target on&nbsp;<b>Cognyte Software Ltd.</b>&nbsp;from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>  <li>Jefferies cut&nbsp;<b>ALX Oncology Holdings Inc.</b>&nbsp;price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>  <li>Bernstein reduced the price target for&nbsp;<b>AGCO Corporation</b>&nbsp;from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>  <li>RBC Capital raised&nbsp;<b>Consolidated Edison, Inc.</b>&nbsp;price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>  <li>Oppenheimer cut&nbsp;<b>Biogen Inc.</b>&nbsp;price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li> </ul></p><p><blockquote><ul><li>巴克莱上调目标价<b>FactSet研究系统公司。</b>从450美元到550美元。FactSet Research股价在盘前交易中上涨1.1%，至479.89美元。</li><li>HC Wainwright&amp;Co.上调目标价<b>奇梅里克斯公司。</b>从21美元到24美元。Chimerix股价在盘前交易中上涨4.4%至6.42美元。</li><li>伯恩斯坦提出<b>帕卡尔公司</b>目标价为94美元至98美元。PACCAR股价在盘前交易中上涨0.8%至84.04美元。</li><li>杰弗里斯削减<b>柔板治疗公司。</b>目标价为46美元至10美元。Adagio Therapeutics股价在盘前交易中下跌7.3%至9.54美元。</li><li>巴克莱提高了目标价<b>耐克公司。</b>从185美元到195美元。耐克股价在盘前交易中上涨0.2%，至166.98美元。</li><li>Needham将目标价下调至<b>科尼特软件有限公司。</b>从36美元到19美元。Cognyte Software股价在盘前交易中下跌1%，至15.54美元。</li><li>杰弗里斯削减<b>ALX肿瘤控股公司。</b>目标价为65美元至25美元。ALX Oncology Holdings股价在盘前交易中下跌1.5%至22.57美元。</li><li>伯恩斯坦降低了目标价<b>AGCO公司</b>从177美元到127美元。爱科股价在盘前交易中下跌1%，至112.95美元。</li><li>加拿大皇家银行筹集的资金<b>联合爱迪生公司。</b>目标价为78美元至85美元。联合爱迪生公司股价周二下跌0.8%，收于83.37美元。</li><li>奥本海默切<b>百健公司。</b>目标价从390美元到350美元。Biogen股价在盘前交易中下跌0.1%，至234.50美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","AGCO":"爱科集团","CGNT":"Cognyte Software Ltd.","FDS":"辉盛研究系统","CMRX":"Chimerix Inc.","PCAR":"帕卡","ED":"爱迪生联合电气","ALXO":"ALX Oncology Holdings","NKE":"耐克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188142807","content_text":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.\nHC Wainwright & Co. raised the price target on Chimerix, Inc. from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.\nBernstein raised PACCAR Inc price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.\nJefferies cut Adagio Therapeutics, Inc. price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.\nBarclays boosted the price target for NIKE, Inc. from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.\nNeedham lowered the price target on Cognyte Software Ltd. from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.\nJefferies cut ALX Oncology Holdings Inc. price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.\nBernstein reduced the price target for AGCO Corporation from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.\nRBC Capital raised Consolidated Edison, Inc. price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.\nOppenheimer cut Biogen Inc. price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.","news_type":1,"symbols_score_info":{"BIIB":0.9,"AGCO":0.9,"CMRX":0.9,"PCAR":0.9,"NKE":0.9,"CGNT":0.9,"ADGI":0.9,"ED":0.9,"ALXO":0.9,"FDS":0.9}},"isVote":1,"tweetType":1,"viewCount":3014,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626406,"gmtCreate":1640185907845,"gmtModify":1640185907845,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691626406","repostId":"1163953446","repostType":4,"repost":{"id":"1163953446","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640182473,"share":"https://www.laohu8.com/m/news/1163953446?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:14","market":"us","language":"en","title":"Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos股价暴跌87%，分析师因lirentelimab数据“令人失望”而下调评级</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1163953446","media":"Tiger Newspress","summary":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s","content":"<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p><p><blockquote>Allakos昨天宣布其后期研究KRYPTOS和Enigma 2未能达到统计显著性，盘前下跌87.4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p><p><blockquote>这些研究达到了其组织学共同主要终点，但未能达到症状终点。</blockquote></p><p> In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p><p><blockquote>在ENIGMA中，接受lirentelimab治疗的患者在第23-24周的总症状评分-6（TSS-6）较基线降低了10.0分（基线=29.5），而安慰剂组降低了11.5分（基线=27.7；p=0.343）。</blockquote></p><p> On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p><p><blockquote>在KRYPTOS试验中患者报告的吞咽困难症状问卷的绝对平均变化的第二个共同主要终点上，高剂量组实现了17.4分的降低，低剂量组实现了11.9分的降低，安慰剂实现了14.6分的降低。</blockquote></p><p> Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p><p><blockquote>在这一令人失望的结果之后，几位分析师下调了该股的评级并大幅下调了目标价。</blockquote></p><p> William Blair downgraded the stock to Market Perform from Outperform.</p><p><blockquote>威廉·布莱尔将该股评级从跑赢大盘下调至与大盘持平。</blockquote></p><p> Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p><p><blockquote>该公司的分析师表示，“虽然我们相信lirentelimab已显示出针对嗜酸性粒细胞和肥大细胞的组织学活性的明确证据，但两项研究均未能达到患者报告症状的共同主要终点，引发了这些组织学改善是否可以转化为临床改善的问题。”</blockquote></p><p> With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p><p><blockquote>分析师指出，由于利伦替利单抗的表现比安慰剂差，因此显然存在疑问，为什么II期的干净结果没有转化。</blockquote></p><p> Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p><p><blockquote>Cowen分析师Joseph Thome也将Allakos的评级从跑赢大盘下调至大盘表现，但价格目标(PT)有待管道明确。</blockquote></p><p> SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p><p><blockquote>SVB Leerink分析师Thomas Smith将该股评级从跑赢大盘下调至与大盘持平，PT为17美元。</blockquote></p><p> Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p><p><blockquote>Barclays分析师Carter Gould将该公司对Allakos的PT从36美元下调至8美元，并维持跑输大盘评级。古尔德在一份研究报告中告诉投资者，该公司的主要资产在关键的第三阶段研究中失败了。他认为这是利伦替利单抗的“终结游戏”。</blockquote></p><p> Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p><p><blockquote>摩根士丹利表示，Allakos令人失望的数据增加了嗜酸性胃肠道疾病（EGIDs）的不确定性。</blockquote></p><p> Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p><p><blockquote>杰富瑞(Jefferies)分析师莫里·雷克罗夫特(Maury Raycroft)将Allakos的评级从买入下调至持有。</blockquote></p><p> LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p><p><blockquote>LifeSci Capital分析师Samuel Slutsky将该股评级从跑赢大盘下调至与大盘持平。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos股价暴跌87%，分析师因lirentelimab数据“令人失望”而下调评级</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos股价暴跌87%，分析师因lirentelimab数据“令人失望”而下调评级</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-22 22:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p><p><blockquote>Allakos昨天宣布其后期研究KRYPTOS和Enigma 2未能达到统计显著性，盘前下跌87.4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p><p><blockquote>这些研究达到了其组织学共同主要终点，但未能达到症状终点。</blockquote></p><p> In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p><p><blockquote>在ENIGMA中，接受lirentelimab治疗的患者在第23-24周的总症状评分-6（TSS-6）较基线降低了10.0分（基线=29.5），而安慰剂组降低了11.5分（基线=27.7；p=0.343）。</blockquote></p><p> On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p><p><blockquote>在KRYPTOS试验中患者报告的吞咽困难症状问卷的绝对平均变化的第二个共同主要终点上，高剂量组实现了17.4分的降低，低剂量组实现了11.9分的降低，安慰剂实现了14.6分的降低。</blockquote></p><p> Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p><p><blockquote>在这一令人失望的结果之后，几位分析师下调了该股的评级并大幅下调了目标价。</blockquote></p><p> William Blair downgraded the stock to Market Perform from Outperform.</p><p><blockquote>威廉·布莱尔将该股评级从跑赢大盘下调至与大盘持平。</blockquote></p><p> Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p><p><blockquote>该公司的分析师表示，“虽然我们相信lirentelimab已显示出针对嗜酸性粒细胞和肥大细胞的组织学活性的明确证据，但两项研究均未能达到患者报告症状的共同主要终点，引发了这些组织学改善是否可以转化为临床改善的问题。”</blockquote></p><p> With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p><p><blockquote>分析师指出，由于利伦替利单抗的表现比安慰剂差，因此显然存在疑问，为什么II期的干净结果没有转化。</blockquote></p><p> Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p><p><blockquote>Cowen分析师Joseph Thome也将Allakos的评级从跑赢大盘下调至大盘表现，但价格目标(PT)有待管道明确。</blockquote></p><p> SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p><p><blockquote>SVB Leerink分析师Thomas Smith将该股评级从跑赢大盘下调至与大盘持平，PT为17美元。</blockquote></p><p> Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p><p><blockquote>Barclays分析师Carter Gould将该公司对Allakos的PT从36美元下调至8美元，并维持跑输大盘评级。古尔德在一份研究报告中告诉投资者，该公司的主要资产在关键的第三阶段研究中失败了。他认为这是利伦替利单抗的“终结游戏”。</blockquote></p><p> Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p><p><blockquote>摩根士丹利表示，Allakos令人失望的数据增加了嗜酸性胃肠道疾病（EGIDs）的不确定性。</blockquote></p><p> Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p><p><blockquote>杰富瑞(Jefferies)分析师莫里·雷克罗夫特(Maury Raycroft)将Allakos的评级从买入下调至持有。</blockquote></p><p> LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p><p><blockquote>LifeSci Capital分析师Samuel Slutsky将该股评级从跑赢大盘下调至与大盘持平。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALLK":"Allakos Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163953446","content_text":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.\n\nThe studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.\nIn ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).\nOn the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.\nFollowing this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.\nWilliam Blair downgraded the stock to Market Perform from Outperform.\nAnalysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"\nWith lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.\nCowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.\nSVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.\nBarclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.\nMorgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.\nJefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.\nLifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.","news_type":1,"symbols_score_info":{"ALLK":0.9}},"isVote":1,"tweetType":1,"viewCount":2176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626231,"gmtCreate":1640185895252,"gmtModify":1640185895301,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691626231","repostId":"1157274137","repostType":4,"repost":{"id":"1157274137","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640183410,"share":"https://www.laohu8.com/m/news/1157274137?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:30","market":"us","language":"en","title":"Stocks trade mixed after rally, with tech under pressure<blockquote>股市反弹后涨跌互现，科技股承压</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1157274137","media":"Tiger Newspress","summary":"Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes ra","content":"<p>Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&amp;P 500, Dow and Nasdaq opened in slightly negative territory.</p><p><blockquote>周三股市涨跌互现，周二盘中企稳，主要股指在连续三个交易日下跌后反弹。标普500、道琼斯指数和纳斯达克指数开盘小幅下跌。</blockquote></p><p> With trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.</p><p><blockquote>由于假期缩短的一周交易量相对清淡，投资者继续评估奥密克戎变体的众多发展及其对经济活动的潜在影响。这些更新伴随着美联储明年收紧货币政策的预期。</blockquote></p><p> Omicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now&nbsp;accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests&nbsp;to Americans for free beginning next month.</p><p><blockquote>奥密克戎病毒已经超过其他冠状病毒变种，成为美国的主要毒株，目前约占新感染病例的四分之三。在此背景下，乔·拜登总统周二宣布了一系列应对该病毒的新措施，包括开放更多的联邦COVID-19检测和疫苗接种点，以及从下个月开始向美国人免费提供5亿次家庭快速检测。</blockquote></p><p> \"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"</p><p><blockquote>SoFi投资策略主管Liz Young周二告诉雅虎财经直播：“我认为这是提醒大家市场是领先指标的绝佳时机。因此，市场将会下跌，市场将在坏消息见顶之前触底。”“我们可能还没有听到所有的坏消息。我们的奥密克戎病例肯定还没有达到顶峰。”</blockquote></p><p> \"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"</p><p><blockquote>“但我们在（周二）的行动中看到的是，我们已经经历了三天的抛售。我认为其中一些太过分了，特别是在许多有望表现良好的领域。在重新开放的环境中，”她补充道。“你必须在市场上拥有一些资金，投资于应该以这种特定方式表现良好的领域。航空公司就是其中之一，周期性股票更多。当我们审视当今市场的模式时，我认为这对于未来6至12个月的前景是有意义的。”</blockquote></p><p> Other strategists agreed that investors should brace for more choppiness heading into the end of the year.</p><p><blockquote>其他策略师一致认为，投资者应该为年底前的更多波动做好准备。</blockquote></p><p> \"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"</p><p><blockquote>富国证券股票策略师Anna Han周二对雅虎财经直播表示：“我认为，在经历了几个波动的交易日之后，你自然会得到一点反弹。但市场也在试图定价和消化我们在这里得到的新信息。”“我们有一些关于重建更好的消息被推迟了，我们有更多关于奥密克戎的信息。当我们进入年底时，你会看到这些情况与低流动性相结合，因此我们对波动性并不感到惊讶。”</blockquote></p><p> During a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.</p><p><blockquote>在周二讲话的问答环节中，拜登表示，他和西弗吉尼亚州民主党参议员乔·曼钦（Joe Manchin）将在白宫约1.8万亿美元的重建更好社会政策法案上“有所作为”。曼钦本周早些时候告诉福克斯新闻，他无法支持这项立法，部分原因是持续存在的通胀担忧，这表明如果没有温和派民主党议员的支持，该法案将被否决。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks trade mixed after rally, with tech under pressure<blockquote>股市反弹后涨跌互现，科技股承压</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks trade mixed after rally, with tech under pressure<blockquote>股市反弹后涨跌互现，科技股承压</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-22 22:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&amp;P 500, Dow and Nasdaq opened in slightly negative territory.</p><p><blockquote>周三股市涨跌互现，周二盘中企稳，主要股指在连续三个交易日下跌后反弹。标普500、道琼斯指数和纳斯达克指数开盘小幅下跌。</blockquote></p><p> With trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.</p><p><blockquote>由于假期缩短的一周交易量相对清淡，投资者继续评估奥密克戎变体的众多发展及其对经济活动的潜在影响。这些更新伴随着美联储明年收紧货币政策的预期。</blockquote></p><p> Omicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now&nbsp;accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests&nbsp;to Americans for free beginning next month.</p><p><blockquote>奥密克戎病毒已经超过其他冠状病毒变种，成为美国的主要毒株，目前约占新感染病例的四分之三。在此背景下，乔·拜登总统周二宣布了一系列应对该病毒的新措施，包括开放更多的联邦COVID-19检测和疫苗接种点，以及从下个月开始向美国人免费提供5亿次家庭快速检测。</blockquote></p><p> \"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"</p><p><blockquote>SoFi投资策略主管Liz Young周二告诉雅虎财经直播：“我认为这是提醒大家市场是领先指标的绝佳时机。因此，市场将会下跌，市场将在坏消息见顶之前触底。”“我们可能还没有听到所有的坏消息。我们的奥密克戎病例肯定还没有达到顶峰。”</blockquote></p><p> \"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"</p><p><blockquote>“但我们在（周二）的行动中看到的是，我们已经经历了三天的抛售。我认为其中一些太过分了，特别是在许多有望表现良好的领域。在重新开放的环境中，”她补充道。“你必须在市场上拥有一些资金，投资于应该以这种特定方式表现良好的领域。航空公司就是其中之一，周期性股票更多。当我们审视当今市场的模式时，我认为这对于未来6至12个月的前景是有意义的。”</blockquote></p><p> Other strategists agreed that investors should brace for more choppiness heading into the end of the year.</p><p><blockquote>其他策略师一致认为，投资者应该为年底前的更多波动做好准备。</blockquote></p><p> \"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"</p><p><blockquote>富国证券股票策略师Anna Han周二对雅虎财经直播表示：“我认为，在经历了几个波动的交易日之后，你自然会得到一点反弹。但市场也在试图定价和消化我们在这里得到的新信息。”“我们有一些关于重建更好的消息被推迟了，我们有更多关于奥密克戎的信息。当我们进入年底时，你会看到这些情况与低流动性相结合，因此我们对波动性并不感到惊讶。”</blockquote></p><p> During a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.</p><p><blockquote>在周二讲话的问答环节中，拜登表示，他和西弗吉尼亚州民主党参议员乔·曼钦（Joe Manchin）将在白宫约1.8万亿美元的重建更好社会政策法案上“有所作为”。曼钦本周早些时候告诉福克斯新闻，他无法支持这项立法，部分原因是持续存在的通胀担忧，这表明如果没有温和派民主党议员的支持，该法案将被否决。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157274137","content_text":"Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&P 500, Dow and Nasdaq opened in slightly negative territory.\nWith trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.\nOmicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests to Americans for free beginning next month.\n\"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"\n\"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"\nOther strategists agreed that investors should brace for more choppiness heading into the end of the year.\n\"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"\nDuring a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2616,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626151,"gmtCreate":1640185863507,"gmtModify":1640185863507,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691626151","repostId":"2193419144","repostType":4,"isVote":1,"tweetType":1,"viewCount":3411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":691626231,"gmtCreate":1640185895252,"gmtModify":1640185895301,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089174425482880","idStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691626231","repostId":"1157274137","repostType":4,"repost":{"id":"1157274137","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640183410,"share":"https://www.laohu8.com/m/news/1157274137?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:30","market":"us","language":"en","title":"Stocks trade mixed after rally, with tech under pressure<blockquote>股市反弹后涨跌互现，科技股承压</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1157274137","media":"Tiger Newspress","summary":"Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes ra","content":"<p>Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&amp;P 500, Dow and Nasdaq opened in slightly negative territory.</p><p><blockquote>周三股市涨跌互现，周二盘中企稳，主要股指在连续三个交易日下跌后反弹。标普500、道琼斯指数和纳斯达克指数开盘小幅下跌。</blockquote></p><p> With trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.</p><p><blockquote>由于假期缩短的一周交易量相对清淡，投资者继续评估奥密克戎变体的众多发展及其对经济活动的潜在影响。这些更新伴随着美联储明年收紧货币政策的预期。</blockquote></p><p> Omicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now&nbsp;accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests&nbsp;to Americans for free beginning next month.</p><p><blockquote>奥密克戎病毒已经超过其他冠状病毒变种，成为美国的主要毒株，目前约占新感染病例的四分之三。在此背景下，乔·拜登总统周二宣布了一系列应对该病毒的新措施，包括开放更多的联邦COVID-19检测和疫苗接种点，以及从下个月开始向美国人免费提供5亿次家庭快速检测。</blockquote></p><p> \"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"</p><p><blockquote>SoFi投资策略主管Liz Young周二告诉雅虎财经直播：“我认为这是提醒大家市场是领先指标的绝佳时机。因此，市场将会下跌，市场将在坏消息见顶之前触底。”“我们可能还没有听到所有的坏消息。我们的奥密克戎病例肯定还没有达到顶峰。”</blockquote></p><p> \"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"</p><p><blockquote>“但我们在（周二）的行动中看到的是，我们已经经历了三天的抛售。我认为其中一些太过分了，特别是在许多有望表现良好的领域。在重新开放的环境中，”她补充道。“你必须在市场上拥有一些资金，投资于应该以这种特定方式表现良好的领域。航空公司就是其中之一，周期性股票更多。当我们审视当今市场的模式时，我认为这对于未来6至12个月的前景是有意义的。”</blockquote></p><p> Other strategists agreed that investors should brace for more choppiness heading into the end of the year.</p><p><blockquote>其他策略师一致认为，投资者应该为年底前的更多波动做好准备。</blockquote></p><p> \"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"</p><p><blockquote>富国证券股票策略师Anna Han周二对雅虎财经直播表示：“我认为，在经历了几个波动的交易日之后，你自然会得到一点反弹。但市场也在试图定价和消化我们在这里得到的新信息。”“我们有一些关于重建更好的消息被推迟了，我们有更多关于奥密克戎的信息。当我们进入年底时，你会看到这些情况与低流动性相结合，因此我们对波动性并不感到惊讶。”</blockquote></p><p> During a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.</p><p><blockquote>在周二讲话的问答环节中，拜登表示，他和西弗吉尼亚州民主党参议员乔·曼钦（Joe Manchin）将在白宫约1.8万亿美元的重建更好社会政策法案上“有所作为”。曼钦本周早些时候告诉福克斯新闻，他无法支持这项立法，部分原因是持续存在的通胀担忧，这表明如果没有温和派民主党议员的支持，该法案将被否决。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks trade mixed after rally, with tech under pressure<blockquote>股市反弹后涨跌互现，科技股承压</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks trade mixed after rally, with tech under pressure<blockquote>股市反弹后涨跌互现，科技股承压</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-22 22:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&amp;P 500, Dow and Nasdaq opened in slightly negative territory.</p><p><blockquote>周三股市涨跌互现，周二盘中企稳，主要股指在连续三个交易日下跌后反弹。标普500、道琼斯指数和纳斯达克指数开盘小幅下跌。</blockquote></p><p> With trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.</p><p><blockquote>由于假期缩短的一周交易量相对清淡，投资者继续评估奥密克戎变体的众多发展及其对经济活动的潜在影响。这些更新伴随着美联储明年收紧货币政策的预期。</blockquote></p><p> Omicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now&nbsp;accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests&nbsp;to Americans for free beginning next month.</p><p><blockquote>奥密克戎病毒已经超过其他冠状病毒变种，成为美国的主要毒株，目前约占新感染病例的四分之三。在此背景下，乔·拜登总统周二宣布了一系列应对该病毒的新措施，包括开放更多的联邦COVID-19检测和疫苗接种点，以及从下个月开始向美国人免费提供5亿次家庭快速检测。</blockquote></p><p> \"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"</p><p><blockquote>SoFi投资策略主管Liz Young周二告诉雅虎财经直播：“我认为这是提醒大家市场是领先指标的绝佳时机。因此，市场将会下跌，市场将在坏消息见顶之前触底。”“我们可能还没有听到所有的坏消息。我们的奥密克戎病例肯定还没有达到顶峰。”</blockquote></p><p> \"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"</p><p><blockquote>“但我们在（周二）的行动中看到的是，我们已经经历了三天的抛售。我认为其中一些太过分了，特别是在许多有望表现良好的领域。在重新开放的环境中，”她补充道。“你必须在市场上拥有一些资金，投资于应该以这种特定方式表现良好的领域。航空公司就是其中之一，周期性股票更多。当我们审视当今市场的模式时，我认为这对于未来6至12个月的前景是有意义的。”</blockquote></p><p> Other strategists agreed that investors should brace for more choppiness heading into the end of the year.</p><p><blockquote>其他策略师一致认为，投资者应该为年底前的更多波动做好准备。</blockquote></p><p> \"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"</p><p><blockquote>富国证券股票策略师Anna Han周二对雅虎财经直播表示：“我认为，在经历了几个波动的交易日之后，你自然会得到一点反弹。但市场也在试图定价和消化我们在这里得到的新信息。”“我们有一些关于重建更好的消息被推迟了，我们有更多关于奥密克戎的信息。当我们进入年底时，你会看到这些情况与低流动性相结合，因此我们对波动性并不感到惊讶。”</blockquote></p><p> During a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.</p><p><blockquote>在周二讲话的问答环节中，拜登表示，他和西弗吉尼亚州民主党参议员乔·曼钦（Joe Manchin）将在白宫约1.8万亿美元的重建更好社会政策法案上“有所作为”。曼钦本周早些时候告诉福克斯新闻，他无法支持这项立法，部分原因是持续存在的通胀担忧，这表明如果没有温和派民主党议员的支持，该法案将被否决。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157274137","content_text":"Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&P 500, Dow and Nasdaq opened in slightly negative territory.\nWith trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.\nOmicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests to Americans for free beginning next month.\n\"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"\n\"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"\nOther strategists agreed that investors should brace for more choppiness heading into the end of the year.\n\"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"\nDuring a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2616,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691625975,"gmtCreate":1640186032395,"gmtModify":1640186032395,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089174425482880","idStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691625975","repostId":"2193192429","repostType":4,"isVote":1,"tweetType":1,"viewCount":2625,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626151,"gmtCreate":1640185863507,"gmtModify":1640185863507,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089174425482880","idStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691626151","repostId":"2193419144","repostType":4,"isVote":1,"tweetType":1,"viewCount":3411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691622121,"gmtCreate":1640185928643,"gmtModify":1640185971826,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089174425482880","idStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691622121","repostId":"2193196162","repostType":4,"isVote":1,"tweetType":1,"viewCount":2364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691622066,"gmtCreate":1640185916183,"gmtModify":1640185916183,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089174425482880","idStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691622066","repostId":"1188142807","repostType":4,"repost":{"id":"1188142807","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640181395,"share":"https://www.laohu8.com/m/news/1188142807?lang=zh_CN&edition=full","pubTime":"2021-12-22 21:56","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188142807","media":"Benzinga","summary":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Researc","content":"<p><ul>  <li>Barclays lifted the price target on&nbsp;<b>FactSet Research Systems Inc.</b>&nbsp;from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>  <li>HC Wainwright &amp; Co. raised the price target on&nbsp;<b>Chimerix, Inc.</b>&nbsp;from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>  <li>Bernstein raised&nbsp;<b>PACCAR Inc</b>&nbsp;price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>  <li>Jefferies cut&nbsp;<b>Adagio Therapeutics, Inc.</b>&nbsp;price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>  <li>Barclays boosted the price target for&nbsp;<b>NIKE, Inc.</b>&nbsp;from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>  <li>Needham lowered the price target on&nbsp;<b>Cognyte Software Ltd.</b>&nbsp;from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>  <li>Jefferies cut&nbsp;<b>ALX Oncology Holdings Inc.</b>&nbsp;price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>  <li>Bernstein reduced the price target for&nbsp;<b>AGCO Corporation</b>&nbsp;from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>  <li>RBC Capital raised&nbsp;<b>Consolidated Edison, Inc.</b>&nbsp;price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>  <li>Oppenheimer cut&nbsp;<b>Biogen Inc.</b>&nbsp;price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li> </ul></p><p><blockquote><ul><li>巴克莱上调目标价<b>FactSet研究系统公司。</b>从450美元到550美元。FactSet Research股价在盘前交易中上涨1.1%，至479.89美元。</li><li>HC Wainwright&amp;Co.上调目标价<b>奇梅里克斯公司。</b>从21美元到24美元。Chimerix股价在盘前交易中上涨4.4%至6.42美元。</li><li>伯恩斯坦提出<b>帕卡尔公司</b>目标价为94美元至98美元。PACCAR股价在盘前交易中上涨0.8%至84.04美元。</li><li>杰弗里斯削减<b>柔板治疗公司。</b>目标价为46美元至10美元。Adagio Therapeutics股价在盘前交易中下跌7.3%至9.54美元。</li><li>巴克莱提高了目标价<b>耐克公司。</b>从185美元到195美元。耐克股价在盘前交易中上涨0.2%，至166.98美元。</li><li>Needham将目标价下调至<b>科尼特软件有限公司。</b>从36美元到19美元。Cognyte Software股价在盘前交易中下跌1%，至15.54美元。</li><li>杰弗里斯削减<b>ALX肿瘤控股公司。</b>目标价为65美元至25美元。ALX Oncology Holdings股价在盘前交易中下跌1.5%至22.57美元。</li><li>伯恩斯坦降低了目标价<b>AGCO公司</b>从177美元到127美元。爱科股价在盘前交易中下跌1%，至112.95美元。</li><li>加拿大皇家银行筹集的资金<b>联合爱迪生公司。</b>目标价为78美元至85美元。联合爱迪生公司股价周二下跌0.8%，收于83.37美元。</li><li>奥本海默切<b>百健公司。</b>目标价从390美元到350美元。Biogen股价在盘前交易中下跌0.1%，至234.50美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 21:56</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><ul>  <li>Barclays lifted the price target on&nbsp;<b>FactSet Research Systems Inc.</b>&nbsp;from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>  <li>HC Wainwright &amp; Co. raised the price target on&nbsp;<b>Chimerix, Inc.</b>&nbsp;from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>  <li>Bernstein raised&nbsp;<b>PACCAR Inc</b>&nbsp;price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>  <li>Jefferies cut&nbsp;<b>Adagio Therapeutics, Inc.</b>&nbsp;price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>  <li>Barclays boosted the price target for&nbsp;<b>NIKE, Inc.</b>&nbsp;from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>  <li>Needham lowered the price target on&nbsp;<b>Cognyte Software Ltd.</b>&nbsp;from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>  <li>Jefferies cut&nbsp;<b>ALX Oncology Holdings Inc.</b>&nbsp;price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>  <li>Bernstein reduced the price target for&nbsp;<b>AGCO Corporation</b>&nbsp;from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>  <li>RBC Capital raised&nbsp;<b>Consolidated Edison, Inc.</b>&nbsp;price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>  <li>Oppenheimer cut&nbsp;<b>Biogen Inc.</b>&nbsp;price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li> </ul></p><p><blockquote><ul><li>巴克莱上调目标价<b>FactSet研究系统公司。</b>从450美元到550美元。FactSet Research股价在盘前交易中上涨1.1%，至479.89美元。</li><li>HC Wainwright&amp;Co.上调目标价<b>奇梅里克斯公司。</b>从21美元到24美元。Chimerix股价在盘前交易中上涨4.4%至6.42美元。</li><li>伯恩斯坦提出<b>帕卡尔公司</b>目标价为94美元至98美元。PACCAR股价在盘前交易中上涨0.8%至84.04美元。</li><li>杰弗里斯削减<b>柔板治疗公司。</b>目标价为46美元至10美元。Adagio Therapeutics股价在盘前交易中下跌7.3%至9.54美元。</li><li>巴克莱提高了目标价<b>耐克公司。</b>从185美元到195美元。耐克股价在盘前交易中上涨0.2%，至166.98美元。</li><li>Needham将目标价下调至<b>科尼特软件有限公司。</b>从36美元到19美元。Cognyte Software股价在盘前交易中下跌1%，至15.54美元。</li><li>杰弗里斯削减<b>ALX肿瘤控股公司。</b>目标价为65美元至25美元。ALX Oncology Holdings股价在盘前交易中下跌1.5%至22.57美元。</li><li>伯恩斯坦降低了目标价<b>AGCO公司</b>从177美元到127美元。爱科股价在盘前交易中下跌1%，至112.95美元。</li><li>加拿大皇家银行筹集的资金<b>联合爱迪生公司。</b>目标价为78美元至85美元。联合爱迪生公司股价周二下跌0.8%，收于83.37美元。</li><li>奥本海默切<b>百健公司。</b>目标价从390美元到350美元。Biogen股价在盘前交易中下跌0.1%，至234.50美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","AGCO":"爱科集团","CGNT":"Cognyte Software Ltd.","FDS":"辉盛研究系统","CMRX":"Chimerix Inc.","PCAR":"帕卡","ED":"爱迪生联合电气","ALXO":"ALX Oncology Holdings","NKE":"耐克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188142807","content_text":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.\nHC Wainwright & Co. raised the price target on Chimerix, Inc. from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.\nBernstein raised PACCAR Inc price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.\nJefferies cut Adagio Therapeutics, Inc. price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.\nBarclays boosted the price target for NIKE, Inc. from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.\nNeedham lowered the price target on Cognyte Software Ltd. from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.\nJefferies cut ALX Oncology Holdings Inc. price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.\nBernstein reduced the price target for AGCO Corporation from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.\nRBC Capital raised Consolidated Edison, Inc. price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.\nOppenheimer cut Biogen Inc. price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.","news_type":1,"symbols_score_info":{"BIIB":0.9,"AGCO":0.9,"CMRX":0.9,"PCAR":0.9,"NKE":0.9,"CGNT":0.9,"ADGI":0.9,"ED":0.9,"ALXO":0.9,"FDS":0.9}},"isVote":1,"tweetType":1,"viewCount":3014,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626406,"gmtCreate":1640185907845,"gmtModify":1640185907845,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089174425482880","idStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691626406","repostId":"1163953446","repostType":4,"repost":{"id":"1163953446","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640182473,"share":"https://www.laohu8.com/m/news/1163953446?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:14","market":"us","language":"en","title":"Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos股价暴跌87%，分析师因lirentelimab数据“令人失望”而下调评级</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1163953446","media":"Tiger Newspress","summary":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s","content":"<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p><p><blockquote>Allakos昨天宣布其后期研究KRYPTOS和Enigma 2未能达到统计显著性，盘前下跌87.4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p><p><blockquote>这些研究达到了其组织学共同主要终点，但未能达到症状终点。</blockquote></p><p> In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p><p><blockquote>在ENIGMA中，接受lirentelimab治疗的患者在第23-24周的总症状评分-6（TSS-6）较基线降低了10.0分（基线=29.5），而安慰剂组降低了11.5分（基线=27.7；p=0.343）。</blockquote></p><p> On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p><p><blockquote>在KRYPTOS试验中患者报告的吞咽困难症状问卷的绝对平均变化的第二个共同主要终点上，高剂量组实现了17.4分的降低，低剂量组实现了11.9分的降低，安慰剂实现了14.6分的降低。</blockquote></p><p> Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p><p><blockquote>在这一令人失望的结果之后，几位分析师下调了该股的评级并大幅下调了目标价。</blockquote></p><p> William Blair downgraded the stock to Market Perform from Outperform.</p><p><blockquote>威廉·布莱尔将该股评级从跑赢大盘下调至与大盘持平。</blockquote></p><p> Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p><p><blockquote>该公司的分析师表示，“虽然我们相信lirentelimab已显示出针对嗜酸性粒细胞和肥大细胞的组织学活性的明确证据，但两项研究均未能达到患者报告症状的共同主要终点，引发了这些组织学改善是否可以转化为临床改善的问题。”</blockquote></p><p> With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p><p><blockquote>分析师指出，由于利伦替利单抗的表现比安慰剂差，因此显然存在疑问，为什么II期的干净结果没有转化。</blockquote></p><p> Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p><p><blockquote>Cowen分析师Joseph Thome也将Allakos的评级从跑赢大盘下调至大盘表现，但价格目标(PT)有待管道明确。</blockquote></p><p> SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p><p><blockquote>SVB Leerink分析师Thomas Smith将该股评级从跑赢大盘下调至与大盘持平，PT为17美元。</blockquote></p><p> Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p><p><blockquote>Barclays分析师Carter Gould将该公司对Allakos的PT从36美元下调至8美元，并维持跑输大盘评级。古尔德在一份研究报告中告诉投资者，该公司的主要资产在关键的第三阶段研究中失败了。他认为这是利伦替利单抗的“终结游戏”。</blockquote></p><p> Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p><p><blockquote>摩根士丹利表示，Allakos令人失望的数据增加了嗜酸性胃肠道疾病（EGIDs）的不确定性。</blockquote></p><p> Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p><p><blockquote>杰富瑞(Jefferies)分析师莫里·雷克罗夫特(Maury Raycroft)将Allakos的评级从买入下调至持有。</blockquote></p><p> LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p><p><blockquote>LifeSci Capital分析师Samuel Slutsky将该股评级从跑赢大盘下调至与大盘持平。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos股价暴跌87%，分析师因lirentelimab数据“令人失望”而下调评级</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos股价暴跌87%，分析师因lirentelimab数据“令人失望”而下调评级</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-22 22:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p><p><blockquote>Allakos昨天宣布其后期研究KRYPTOS和Enigma 2未能达到统计显著性，盘前下跌87.4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p><p><blockquote>这些研究达到了其组织学共同主要终点，但未能达到症状终点。</blockquote></p><p> In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p><p><blockquote>在ENIGMA中，接受lirentelimab治疗的患者在第23-24周的总症状评分-6（TSS-6）较基线降低了10.0分（基线=29.5），而安慰剂组降低了11.5分（基线=27.7；p=0.343）。</blockquote></p><p> On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p><p><blockquote>在KRYPTOS试验中患者报告的吞咽困难症状问卷的绝对平均变化的第二个共同主要终点上，高剂量组实现了17.4分的降低，低剂量组实现了11.9分的降低，安慰剂实现了14.6分的降低。</blockquote></p><p> Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p><p><blockquote>在这一令人失望的结果之后，几位分析师下调了该股的评级并大幅下调了目标价。</blockquote></p><p> William Blair downgraded the stock to Market Perform from Outperform.</p><p><blockquote>威廉·布莱尔将该股评级从跑赢大盘下调至与大盘持平。</blockquote></p><p> Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p><p><blockquote>该公司的分析师表示，“虽然我们相信lirentelimab已显示出针对嗜酸性粒细胞和肥大细胞的组织学活性的明确证据，但两项研究均未能达到患者报告症状的共同主要终点，引发了这些组织学改善是否可以转化为临床改善的问题。”</blockquote></p><p> With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p><p><blockquote>分析师指出，由于利伦替利单抗的表现比安慰剂差，因此显然存在疑问，为什么II期的干净结果没有转化。</blockquote></p><p> Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p><p><blockquote>Cowen分析师Joseph Thome也将Allakos的评级从跑赢大盘下调至大盘表现，但价格目标(PT)有待管道明确。</blockquote></p><p> SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p><p><blockquote>SVB Leerink分析师Thomas Smith将该股评级从跑赢大盘下调至与大盘持平，PT为17美元。</blockquote></p><p> Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p><p><blockquote>Barclays分析师Carter Gould将该公司对Allakos的PT从36美元下调至8美元，并维持跑输大盘评级。古尔德在一份研究报告中告诉投资者，该公司的主要资产在关键的第三阶段研究中失败了。他认为这是利伦替利单抗的“终结游戏”。</blockquote></p><p> Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p><p><blockquote>摩根士丹利表示，Allakos令人失望的数据增加了嗜酸性胃肠道疾病（EGIDs）的不确定性。</blockquote></p><p> Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p><p><blockquote>杰富瑞(Jefferies)分析师莫里·雷克罗夫特(Maury Raycroft)将Allakos的评级从买入下调至持有。</blockquote></p><p> LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p><p><blockquote>LifeSci Capital分析师Samuel Slutsky将该股评级从跑赢大盘下调至与大盘持平。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALLK":"Allakos Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163953446","content_text":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.\n\nThe studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.\nIn ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).\nOn the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.\nFollowing this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.\nWilliam Blair downgraded the stock to Market Perform from Outperform.\nAnalysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"\nWith lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.\nCowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.\nSVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.\nBarclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.\nMorgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.\nJefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.\nLifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.","news_type":1,"symbols_score_info":{"ALLK":0.9}},"isVote":1,"tweetType":1,"viewCount":2176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}